218 related articles for article (PubMed ID: 16141798)
1. Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil.
Hitre E; Budai B; Adleff V; Czeglédi F; Horváth Z; Gyergyay F; Lövey J; Kovács T; Orosz Z; Láng I; Kásler M; Kralovánszky J
Pharmacogenet Genomics; 2005 Oct; 15(10):723-30. PubMed ID: 16141798
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
[TBL] [Abstract][Full Text] [Related]
3. Combination of polymorphisms within 5' and 3' untranslated regions of thymidylate synthase gene modulates survival in 5 fluorouracil-treated colorectal cancer patients.
Fernández-Contreras ME; Sánchez-Hernández JJ; González E; Herráez B; Domínguez I; Lozano M; García De Paredes ML; Muñoz A; Gamallo C
Int J Oncol; 2009 Jan; 34(1):219-29. PubMed ID: 19082493
[TBL] [Abstract][Full Text] [Related]
4. Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer.
Tsuji T; Hidaka S; Sawai T; Nakagoe T; Yano H; Haseba M; Komatsu H; Shindou H; Fukuoka H; Yoshinaga M; Shibasaki S; Nanashima A; Yamaguchi H; Yasutake T; Tagawa Y
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3700-4. PubMed ID: 14506161
[TBL] [Abstract][Full Text] [Related]
5. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy.
Lecomte T; Ferraz JM; Zinzindohoué F; Loriot MA; Tregouet DA; Landi B; Berger A; Cugnenc PH; Jian R; Beaune P; Laurent-Puig P
Clin Cancer Res; 2004 Sep; 10(17):5880-8. PubMed ID: 15355920
[TBL] [Abstract][Full Text] [Related]
6. Thymidylate synthase polymorphism in sporadic colorectal and gastric cancer in Tunisian population: a predictive role in 5-fluorouracil based chemotherapy treatment.
Baroudi O; Baroudi T; Omrane I; Moussa A; Mezlini A; Ayari H; Guermazi S; Bahloul A; Bouzaienne H; Uhrhammer N; Bignon YJ; El-Gaaied AB; Bougatef K
Med Oncol; 2014 Feb; 31(2):825. PubMed ID: 24415354
[TBL] [Abstract][Full Text] [Related]
7. Thymidylate synthase gene polymorphism predicts disease free survival in stage II-III rectal adenocarcinoma patients receiving adjuvant 5-FU-based chemotherapy.
Su X; Li S; Zhang H; Xiao H; Chen C; Wang G
Chin Clin Oncol; 2019 Jun; 8(3):28. PubMed ID: 30823845
[TBL] [Abstract][Full Text] [Related]
8. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil.
Iacopetta B; Grieu F; Joseph D; Elsaleh H
Br J Cancer; 2001 Sep; 85(6):827-30. PubMed ID: 11556832
[TBL] [Abstract][Full Text] [Related]
9. Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers.
Morganti M; Ciantelli M; Giglioni B; Putignano AL; Nobili S; Papi L; Landini I; Napoli C; Valanzano R; Cianchi F; Boddi V; Tonelli F; Cortesini C; Mazzei T; Genuardi M; Mini E
Eur J Cancer; 2005 Sep; 41(14):2176-83. PubMed ID: 16182121
[TBL] [Abstract][Full Text] [Related]
10. Heterozygote deficiency in thymidylate synthase enhancer region polymorphism genotype distribution in Hungarian colorectal cancer patients.
Adleff V; Hitre E; Köves I; Orosz Z; Hajnal A; Kralovánszky J
Int J Cancer; 2004 Mar; 108(6):852-6. PubMed ID: 14712487
[TBL] [Abstract][Full Text] [Related]
11. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
[TBL] [Abstract][Full Text] [Related]
12. Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment.
Dotor E; Cuatrecases M; Martínez-Iniesta M; Navarro M; Vilardell F; Guinó E; Pareja L; Figueras A; Molleví DG; Serrano T; de Oca J; Peinado MA; Moreno V; Germà JR; Capellá G; Villanueva A
J Clin Oncol; 2006 Apr; 24(10):1603-11. PubMed ID: 16575011
[TBL] [Abstract][Full Text] [Related]
13. Polymorphisms in the enhancer region of the thymidylate synthase gene are associated with thymidylate synthase levels in normal tissues but not in malignant tissues of patients with colorectal cancer.
Mauritz R; Giovannetti E; Beumer IJ; Smid K; Van Groeningen CJ; Pinedo HM; Peters GJ
Clin Colorectal Cancer; 2009 Jul; 8(3):146-54. PubMed ID: 19632929
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses.
Etienne MC; Chazal M; Laurent-Puig P; Magné N; Rosty C; Formento JL; Francoual M; Formento P; Renée N; Chamorey E; Bourgeon A; Seitz JF; Delpero JR; Letoublon C; Pezet D; Milano G
J Clin Oncol; 2002 Jun; 20(12):2832-43. PubMed ID: 12065560
[TBL] [Abstract][Full Text] [Related]
15. Loss of heterozygosity at the thymidylate synthase (TS) locus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene.
Uchida K; Hayashi K; Kawakami K; Schneider S; Yochim JM; Kuramochi H; Takasaki K; Danenberg KD; Danenberg PV
Clin Cancer Res; 2004 Jan; 10(2):433-9. PubMed ID: 14760062
[TBL] [Abstract][Full Text] [Related]
16. Thymidylate synthase expression and genotype have no major impact on the clinical outcome of colorectal cancer patients treated with 5-fluorouracil.
Vignoli M; Nobili S; Napoli C; Putignano AL; Morganti M; Papi L; Valanzano R; Cianchi F; Tonelli F; Mazzei T; Mini E; Genuardi M
Pharmacol Res; 2011 Sep; 64(3):242-8. PubMed ID: 21536130
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of thymidylate synthase polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy.
Arrazubi V; Suárez J; Guerrero D; Gómez M; Viúdez A; Arias F; Balén E; Vera R
Colorectal Dis; 2013 Apr; 15(4):428-35. PubMed ID: 22958523
[TBL] [Abstract][Full Text] [Related]
18. Thymidylate synthase gene polymorphism and survival of colorectal cancer patients receiving adjuvant 5-fluorouracil.
Sulzyc-Bielicka V; Bielicki D; Binczak-Kuleta A; Kaczmarczyk M; Pioch W; Machoy-Mokrzynska A; Ciechanowicz A; Gołębiewska M; Drozdzik M
Genet Test Mol Biomarkers; 2013 Nov; 17(11):799-806. PubMed ID: 23968134
[TBL] [Abstract][Full Text] [Related]
19. The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population.
Huang ZH; Hua D; Li LH
Cancer Chemother Pharmacol; 2009 Apr; 63(5):911-8. PubMed ID: 18704422
[TBL] [Abstract][Full Text] [Related]
20. Influence of thymidylate synthase DNA polymorphisms and gender on the clinical evolution of patients with advanced colorectal cancer.
Fernández-Contreras ME; Sánchez-Hernández JJ; Guijarro M; Gisbert JP; Rivas N; García de Paredes ML; Hinojar-Gutiérrez A; Gamallo C
Oncol Rep; 2010 May; 23(5):1393-400. PubMed ID: 20372856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
